Total Payments
$13,046
2024 Payments
$396.19
Companies
30
Transactions
139
Medicare Patients
1,283
Medicare Billing
$208,054
Payment Breakdown by Category
Travel$5,503 (42.2%)
Food & Beverage$3,630 (27.8%)
Research$2,667 (20.4%)
Consulting$1,245 (9.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $5,503 | 28 | 42.2% |
| Food and Beverage | $3,630 | 89 | 27.8% |
| Unspecified | $2,667 | 18 | 20.4% |
| Consulting Fee | $1,245 | 4 | 9.5% |
Payments by Type
General
$10,379
121 transactions
Research
$2,667
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $2,888 | 21 | $0 (2022) |
| Stryker Corporation | $1,548 | 11 | $0 (2022) |
| Shionogi Inc | $1,461 | 3 | $0 (2023) |
| Medtronic, Inc. | $1,195 | 15 | $0 (2023) |
| Janssen Research & Development, LLC | $968.34 | 8 | $0 (2023) |
| ABBVIE INC. | $793.14 | 7 | $0 (2022) |
| ZOLL Medical Corporation | $746.67 | 1 | $0 (2022) |
| Siemens Medical Solutions USA, Inc. | $701.96 | 5 | $0 (2018) |
| Medtronic USA, Inc. | $552.66 | 6 | $0 (2020) |
| UCB, Inc. | $400.22 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $396.19 | 2 | Becton, Dickinson and Company ($373.75) |
| 2023 | $2,573 | 16 | Shionogi Inc ($1,461) |
| 2022 | $3,665 | 34 | Medtronic, Inc. ($1,048) |
| 2021 | $523.71 | 13 | Terumo Medical Corporation ($134.06) |
| 2020 | $190.46 | 5 | CHIESI USA, INC. ($126.00) |
| 2019 | $703.40 | 10 | Medtronic USA, Inc. ($423.66) |
| 2018 | $3,088 | 25 | Biogen, Inc. ($1,874) |
| 2017 | $1,907 | 34 | Stryker Corporation ($1,321) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $373.75 | General |
| 02/15/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Neurology | ||||||
| 11/01/2023 | Shionogi Inc | — | Travel and Lodging | In-kind items and services | $621.71 | General |
| 11/01/2023 | Shionogi Inc | — | Travel and Lodging | In-kind items and services | $494.94 | General |
| 11/01/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $344.83 | General |
| 10/17/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: Neurology | ||||||
| 09/11/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $249.32 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $52.72 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 09/11/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 07/27/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $376.30 | General |
| 04/26/2023 | Balt USA, LLC | ECLIPSE 2L (Device) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Neurology | ||||||
| 03/20/2023 | Medtronic, Inc. | RELIANT (Device) | Consulting Fee | Cash or cash equivalent | $35.00 | General |
| Category: Catheters | ||||||
| 02/27/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $33.39 | General |
| Category: Neurology | ||||||
| 02/03/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Rare Disease | ||||||
| 11/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $245.37 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $71.43 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $60.40 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $22.79 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $22.79 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $245.37 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 11/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $124.99 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | Biogen, Inc. | $1,874 | 11 |
| A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ABBVIE INC. | $793.14 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 237 | 329 | $266,482 | $40,149 |
| 2022 | 12 | 367 | 462 | $551,359 | $56,546 |
| 2021 | 12 | 351 | 455 | $491,490 | $58,048 |
| 2020 | 12 | 328 | 444 | $404,422 | $53,311 |
Total Patients
1,283
Total Services
1,690
Medicare Billing
$208,054
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 49 | 95 | $62,415 | $15,320 | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 59 | $20,535 | $7,322 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 82 | $20,828 | $6,600 | 31.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 39 | $9,867 | $3,297 | 33.4% |
| 36223 | Insertion of tube into intracranial artery for diagnosis or treatment with review by radiologist | Facility | 2023 | 15 | 15 | $80,570 | $3,249 | 4.0% |
| 36226 | Insertion of tube into brain artery for diagnosis or treatment with review by radiologist | Facility | 2023 | 12 | 12 | $63,738 | $1,856 | 2.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,904 | $1,595 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $2,625 | $909.30 | 34.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 57 | 108 | $70,956 | $17,488 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 73 | 91 | $23,114 | $7,580 | 32.8% |
| 36224 | Insertion of tube into internal neck artery for diagnosis or treatment with review by radiologist | Facility | 2022 | 19 | 22 | $122,549 | $6,005 | 4.9% |
| 36223 | Insertion of tube into intracranial artery for diagnosis or treatment with review by radiologist | Facility | 2022 | 27 | 28 | $151,932 | $5,486 | 3.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 69 | $17,457 | $5,070 | 29.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $13,776 | $4,217 | 30.6% |
| 36226 | Insertion of tube into brain artery for diagnosis or treatment with review by radiologist | Facility | 2022 | 22 | 24 | $127,475 | $3,952 | 3.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 22 | $7,695 | $2,841 | 36.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $4,980 | $1,537 | 30.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 16 | 16 | $5,056 | $1,210 | 23.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $3,444 | $916.13 | 26.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 25 | 25 | $2,925 | $242.40 | 8.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 60 | 117 | $76,869 | $19,877 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 61 | 97 | $24,541 | $7,682 | 31.3% |
| 36224 | Insertion of catheter into internal carotid artery on one side of neck for diagnosis or treatment including radiological supervision and interpretation | Facility | 2021 | 19 | 20 | $130,052 | $6,961 | 5.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 37 | 37 | $18,204 | $5,467 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 54 | $13,716 | $4,269 | 31.1% |
About Wei Liu
Wei Liu is a Neurology healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720277684.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Wei Liu has received a total of $13,046 in payments from pharmaceutical and medical device companies, with $396.19 received in 2024. These payments were reported across 139 transactions from 30 companies. The most common payment nature is "Travel and Lodging" ($5,503).
As a Medicare-enrolled provider, Liu has provided services to 1,283 Medicare beneficiaries, totaling 1,690 services with total Medicare billing of $208,054. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Diagnostic Neuroimaging, Neuroradiology
- Location Louisville, KY
- Active Since 10/17/2007
- Last Updated 03/14/2019
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1720277684
Products in Payments
- Trevo (Device) $1,321
- Artis Q (Device) $701.96
- Pipeline (Device) $434.97
- Briviact (Drug) $362.34
- TREVO (Device) $202.47
- CLEVIPREX (Drug) $151.77
- APTIOM (Drug) $138.44
- GLIDESHEATH SLENDER (Device) $134.06
- Beacon (Device) $132.79
- CLEVIPREX 25MG/50ML (Drug) $126.00
- Confirm Rx (Device) $124.87
- OFIRMEV (Drug) $122.02
- Solitaire (Device) $117.69
- ELIQUIS (Drug) $91.56
- ARES (Device) $90.00
- LINQ II (Device) $69.43
- Vimpat (Drug) $37.88
- AUBAGIO (Drug) $36.48
- RELIANT (Device) $35.00
- Reveal LINQ (Device) $33.89
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Louisville
Adolfo Ramirez-Zamora, M.d, M.D
Neurology — Payments: $360,493
Neurology $360,493
Dr. Kristi Nord, M.d, M.D
Neurology — Payments: $342,417
Neurology $342,417
Dr. Brian Plato, D.o, D.O
Neurology — Payments: $309,983
Neurology $309,983
Dr. Angela Hardwick, M.d, M.D
Neurology — Payments: $259,489
Neurology $259,489
Jeffrey Frank, Md, MD
Neurology — Payments: $232,884
Neurology $232,884
Vinay Puri, M.d, M.D
Neurology — Payments: $225,192
Neurology $225,192